MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - pharmaceuticals
- NEULAND LABS - MYLAN (US)
NEULAND LABS vs MYLAN (US) - Comparison Results
MYLAN (US)
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
Financials
 NEULAND LABS  MYLAN |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| NEULAND LABS Mar-20 |
MYLAN Dec-18 |
NEULAND LABS/ MYLAN |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 754 | 3,554 | - | |
| Low | Rs | 247 | 1,956 | - | |
| Sales per share (Unadj.) | Rs | 594.5 | 1,635.5 | - | |
| Earnings per share (Unadj.) | Rs | 12.6 | 44.4 | - | |
| Cash flow per share (Unadj.) | Rs | 37.0 | 350.6 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.4 | 0 | - | |
| Book value per share (Unadj.) | Rs | 553.4 | 1,769.3 | - | |
| Shares outstanding (eoy) | m | 12.83 | 514.50 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 0.8 | 1.7 | 50.0% | |
| Avg P/E ratio | x | 39.6 | 62.0 | 63.9% | |
| P/CF ratio (eoy) | x | 13.5 | 7.9 | 172.1% | |
| Price / Book Value ratio | x | 0.9 | 1.6 | 58.1% | |
| Dividend payout | % | 15.8 | 0 | - | |
| Avg Mkt Cap | Rs m | 6,421 | 1,417,614 | 0.5% | |
| No. of employees | `000 | 1.3 | 35.0 | 3.7% | |
| Total wages/salary | Rs m | 1,236 | 0 | - | |
| Avg. sales/employee | Rs Th | 5,949.4 | 24,041.6 | 24.7% | |
| Avg. wages/employee | Rs Th | 963.8 | 0 | - | |
| Avg. net profit/employee | Rs Th | 126.4 | 652.8 | 19.4% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 7,627 | 841,456 | 0.9% | |
| Other income | Rs m | 39 | 0 | - | |
| Total revenues | Rs m | 7,666 | 841,456 | 0.9% | |
| Gross profit | Rs m | 1,019 | 217,738 | 0.5% | |
| Depreciation | Rs m | 313 | 157,554 | 0.2% | |
| Interest | Rs m | 216 | 40,471 | 0.5% | |
| Profit before tax | Rs m | 529 | 19,713 | 2.7% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 367 | -3,136 | -11.7% | |
| Profit after tax | Rs m | 162 | 22,849 | 0.7% | |
| Gross profit margin | % | 13.4 | 25.9 | 51.6% | |
| Effective tax rate | % | 69.4 | -15.9 | -436.1% | |
| Net profit margin | % | 2.1 | 2.7 | 78.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 5,152 | 469,868 | 1.1% | |
| Current liabilities | Rs m | 3,576 | 342,586 | 1.0% | |
| Net working cap to sales | % | 20.7 | 15.1 | 136.6% | |
| Current ratio | x | 1.4 | 1.4 | 105.0% | |
| Inventory Days | Days | 105 | 84 | 125.7% | |
| Debtors Days | Days | 91 | 93 | 97.4% | |
| Net fixed assets | Rs m | 3,969 | 163,229 | 2.4% | |
| Share capital | Rs m | 129 | 448 | 28.8% | |
| Net worth | Rs m | 7,100 | 910,302 | 0.8% | |
| Long term debt | Rs m | 774 | 982,508 | 0.1% | |
| Total assets | Rs m | 12,310 | 2,441,784 | 0.5% | |
| Interest coverage | x | 3.5 | 1.5 | 232.2% | |
| Debt to equity ratio | x | 0.1 | 1.1 | 10.1% | |
| Sales to assets ratio | x | 0.6 | 0.3 | 179.8% | |
| Return on assets | % | 3.1 | 2.6 | 118.4% | |
| Return on equity | % | 2.3 | 2.5 | 91.0% | |
| Return on capital | % | 9.5 | 3.2 | 297.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 573 | 174,855 | 0.3% | |
| From Investments | Rs m | -487 | -90,381 | 0.5% | |
| From Financial Activity | Rs m | -55 | -81,458 | 0.1% | |
| Net Cashflow | Rs m | 33 | 1,449 | 2.3% | |
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 74.67 Rs / USD
Compare NEULAND LABS With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare NEULAND LABS With: CIPLA AJANTA PHARMA SUVEN LIFE SCIENCES ALEMBIC PHARMA FDC
Today's Market
Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Related Views On News
NEULAND LABS Announces Quarterly Results (3QFY21); Net Profit Up 141.5% (Quarterly Result Update)
Feb 3, 2021 | Updated on Feb 3, 2021For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.
NEULAND LABS 2019-20 Annual Report Analysis (Annual Result Update)
Sep 2, 2020 | Updated on Sep 2, 2020Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
More Views on NewsMost Popular
A Critical Update on the Market (Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis (Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy (Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers (Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More
